{"title":"Hidradénite suppurée : quels liens et differences avec la maladie de Crohn ?","authors":"A. P Villani","doi":"10.1016/S2667-0623(25)00061-3","DOIUrl":null,"url":null,"abstract":"<div><div>Hidradenitis suppurativa (HS) and Crohn's disease (CD) share close epidemiological and pathophysiological links, suggesting common inflammatory mechanisms. Patients with CD have an increased risk of developing HS and vice versa. Genetic factors, such as NOD2 mutations, as well as immune responses skewed towards the Th1/Th17 pathways, are involved. Clinically, these diseases exhibit similarities, including fistula formation and recurrent chronic inflammation. Therapeutically, anti-TNFα agents are effective in both conditions, whereas anti-IL17 therapies, beneficial in HS, worsen CD. These findings highlight the need for a multidisciplinary and tailored management approach.</div></div>","PeriodicalId":100088,"journal":{"name":"Annales de Dermatologie et de Vénéréologie - FMC","volume":"5 2","pages":"Pages 2S2-2S6"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de Dermatologie et de Vénéréologie - FMC","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667062325000613","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Hidradenitis suppurativa (HS) and Crohn's disease (CD) share close epidemiological and pathophysiological links, suggesting common inflammatory mechanisms. Patients with CD have an increased risk of developing HS and vice versa. Genetic factors, such as NOD2 mutations, as well as immune responses skewed towards the Th1/Th17 pathways, are involved. Clinically, these diseases exhibit similarities, including fistula formation and recurrent chronic inflammation. Therapeutically, anti-TNFα agents are effective in both conditions, whereas anti-IL17 therapies, beneficial in HS, worsen CD. These findings highlight the need for a multidisciplinary and tailored management approach.